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Abstract
Photodynamic therapy (PDT), which utilizes the combination of light and a photosen-
sitizing drug to cause tissue damages, has emerged as a novel clinical approach for the
treatment of numerous cancers, as well as some other non-malignant conditions. Al-
though a few photosensitizers have been approved for clinical uses, the mechanism of
drug action, especially the initial photochemical reactions that lead to the formation of
the reactive oxygen species (ROS), is still not well understood. Moreover, the PDT effi-
ciency of currently used drugs is limited due to the strong attenuation of light by tissues
in the wavelength range of 630-690 nm, where these drugs are photo-activated. Pho-
tosensitizers which are sensitive to near infrared (NIR) light are believed to be able to
overcome this limitation.
In this thesis work, the molecular mechanism of action of indocyanine green (ICG),
a potential NIR PDT drug, was investigated using our femtosecond time-resolved laser
spectroscopy. Femtosecond time-resolved fluorescence decay profiles of ICG in water
were obtained using the fluorescence up-conversion technique. The lifetime of ICG ex-
cited singlet state was determined to be about 150 ps, directly from the fluorescence
decay kinetic traces. The excited triplet-state yield of ICG in water was found to be
extremely low, according to the result of the ground-state bleaching recovery measure-
ment. This observation is contrary to the conventional understanding that the ROS would
be generated mainly from the excited triplet state of the photosensitizer and, therefore,
suggests the existence of a new reaction pathway. Pump-probe transient absorption
spectroscopy was applied to study the reaction between ICG and oxygen in more de-
tails. The results reveal that the formation of ICG and oxygen ground-state complexes
([ICG]m:[O2]n) is a key step in the generation of the ROS. Electron transfer from the
excited singlet state of ICG to oxygen has been proposed to be a possible pathway for
the generation of ROS.
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Cancer is a leading cause of human death. It can be treated by surgery, chemotherapy,
radiotherapy, or other methods. Photodynamic therapy (PDT), which involves the ad-
ministration of photosensitizing drugs and subsequent exposure of the tissue to light, has
emerged as a novel clinical approach for the treatment of various tumors and some other
non-malignant conditions [1, 2]. Due to the selectivity of drug uptake [3] and the control
of light delivery, PDT has the potential of inducing effective cytotoxicity in malignant
tissue and limited damage to the surrounding healthy tissues. Therefore, PDT has supe-
rior properties compared with conventional cancer therapies such as chemotherapy and
radiotherapy: it is selective, noninvasive, and has few side effects. Over the past 30 years,
PDT has been successfully applied for the treatment of a variety types of cancers, such
as early lung cancers not suitable for resection [4, 5], brain tumors [6, 7], head and neck
lesions [8, 9], and rectal cancer [10]. A few PDT sensitizers have been approved for
clinical uses.
The therapeutic effect of PDT is generally believed to be mainly from the reactive
oxygen species (ROS) generated by the reaction of the excited photosensitizer molecules
with oxygen. At the cellular and tissue levels, the ROS can cause cellular or vascular
damages and have immunological effects [11]. However, at the molecular level, the
mechanisms for drug action, especially the very initial photochemical reactions leading
to the generation of the ROS, have only been poorly understood. Moreover, the efficiency
of currently used PDT drugs is limited by the light penetration depth in tissue, since the
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absorption of these drugs lies in the visible light wavelength range (400 to 700 nm),
where the attenuation of light by tissue is strong [12].
One of the current research focuses is to develop new photosensitizers that are sensi-
tive to near-infrared (NIR) light. Indocyanine green (ICG), which has a strong absorption
band in the range of human tissue optical window [12], is a potential NIR PDT sensitizer.
In this thesis, real-time studies of the reaction mechanisms of ICG in water have been
performed using high-sensitivity femtosecond time-resolved laser spectroscopy. A new
reaction pathway for the generation of ROS has been proposed. This study thus provides
new insight into the molecular mechanism for the formation of ROS in PDT.
1.1 Cancer and Cancer Treatment
Cancer is a disease characterized by uncontrolled cell growth and division, invasion and
sometimes metastasis (the spread of cancer cells from their primary site to a remote
organ). The process of cancer development may take years before clinical signs are evi-
dent. This is a multistage process with accumulation of “permanent new characters” [13]
as a result of exposure to carcinogens, which refer to harmful molecules or conditions
originating from within or outside the body. The most common examples of carcinogens
are:
• chemicals such as benzene, kepone,and asbstos,
• microbial carcinogens such as aflatoxin B1,
• viruses such as Hepatitis B and human papilloma viruses,
• sources of ionizing radiation such as radon gas.
In most cases, cancers are sporadic (that is, not inherited). But a few syndromes have
been found to be hereditable. For example, inherited mutations in the genes BRCA1
(breast cancer 1) and BRCA2 (breast cancer 2) are associated with an elevated risk of
breast cancer [14, 15] and ovarian cancer [16]; hereditary nonpolyposis colorectal cancer
(HNPCC, also known as Lynch syndrome) can include familial cases of colon cancer,
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uterine cancer, gastric cancer, and ovarian cancer, without a preponderance of colon
polyps [17]; retinoblastoma, when occurring in young children, is due to a hereditary
mutation in the retinoblastoma gene [18].
Currently, there are a number of therapies available for the treatment of cancers, such
as surgery, chemotherapy, radiotherapy, immunotherapy, monoclonal antibody therapy,
or a combination of these approaches. The choice of therapy is mainly based on the type
and stage of the disease, as well as the general condition of the patient.
1.1.1 Surgery
Surgery is the most frequently used approach for the treatment of solid tumors via the
removal of either the tumor or the entire organ. It is often combined with other cancer
treatments, such as chemotherapy and radiotherapy, depending on the type and stage of
the cancer. Surgery is also necessary in order to determine the type, stage, and extent of
spread of tumors.
In principle, if entirely removed, solid tumors can be cured by surgery. However,
in practice, a single cancer cell is invisible to the naked eye but can regrow into a new
tumor (recurrence). When the cancer cell has metastasized to other sites prior to surgery,
complete excision is impossible.
Side effects including anesthesia complications, infections, and immune suppression
also exist after surgical removal of tumors. Sometimes, the removal of the primary tumor
may even stimulate cancer metastasis [19, 20], which is associated with poorer survival.
Moreover, the reason why the spread begins rapidly following surgery is still not fully
understood.
1.1.2 Radiotherapy
Ionizing radiation is used in radiotherapy to damage or kill cancer cells by damaging their
genetic material, making it impossible for these cells to continue to grow and divide.
Although radiation damages both cancerous and normal cells, most normal cells can
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recover and function properly. Thus, it is usually given in fractions, which allows the
healthy tissue to recover at the intervals. As a result, the effects of radiation therapy are
localized.
Radiotherapy may be applied pre-operatively to shrink the tumor in order to facilitate
surgery, or given postoperatively as adjuvant therapy to reduce the probability of local
recurrence. Almost every type of solid tumor and some leukemia and lymphoma can be
treated by radiotherapy.
Radiotherapy does have potential disadvantages. Despite huge improvements achieved
in reducing severe side effects such as skin burns and scarring, side effects such as tired-
ness, local skin changes (itching, tenderness, swelling or soreness), nausea, and vomiting
may continue for a few weeks. Moreover, the therapeutic efficiency of radiotherapy for
solid tumors with hypoxic regions is limited due to resistance of hypoxic cells to ionizing
radiation [21].
1.1.3 Chemotherapy
Chemotherapy is the treatment of cancer via application of anticancer drugs which can
destroy cancer cells or inhibit their growth. Unlike surgery or radiotherapy, chemother-
apy is systemic. Its selectivity mainly relies on the selective uptake of the drug molecules
by the cancer cells. In general, chemotherapy affects rapidly dividing cells; chemother-
apy drugs may interfere with cell division in various ways, for example with the dupli-
cation of DNA or the separation of newly formed chromosomes.
Pre-operative chemotherapy may be used to reduce the size of the tumor, to facilitate
complete surgical excision, while adjuvant chemotherapy is applied to decrease the rate
of relapse or improve survival after surgery or radiotherapy treatment. Chemotherapy is
also used to relieve symptoms and prolong life when a cure is not possible.
Chemotherapy has the potential of damaging healthy tissues, especially those with a
high replacement rate (e.g. the intestinal lining), since it targets all rapidly dividing cells
without specificity. Numerous side effects can thus occur following treatment. These
include pain, diarrhea, constipation, mouth sores, hair loss, nausea and vomiting, as
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well as blood-related side effects. Another drawback of chemotherapy comes from the
occurrence of drug resistance. Often, if a cancer becomes resistant to one drug, it is more
likely to be resistant to other drugs [22]. Therefore, it is especially important to choose
the best possible treatment protocol.
By using surgery or radiotherapy, localized cancers can usually be effectively treated,
but more than 50% of the cancers have already metastasized when diagnosed [23].
Chemotherapy can be used to kill cancer cells throughout the body. Unfortunately, cur-
rently available chemotherapy drugs are not specific for cancer cells; they generally at-
tack all dividing cells and, therefore, have strong side effects. In recent years, much
progress have been made in cancer diagnosis and treatment. Various targeted therapies
are being developed in an attempt to attack specific targets involved in carcinogenesis and
tumor growth such as HER2 (human epidermal growth factor receptor 2) [24] and VEGF
(vascular endothelial growth factor) [25]. Several compounds have shown promise in the
management of various cancers [26].
In summary, although significant advances have been made over the past decades,
the survival rate of cancer patients, unless detected in the early stage, is still very low.
More effective cancer treatment strategies and new drugs are still urgently needed. A bet-
ter understanding of drug action mechanisms may facilitate the process of drug discovery
[27].
1.2 Photodynamic Therapy
Cell death induced by the interaction of light and chemicals was first reported more
than one hundred years ago by a German medical student named Oscar Raab [28]. The
medical application of photodynamic therapy (PDT) was first described in 1903 by von
Tappeiner and Jesionek, who used the combination of light and topically applied eosin
to treat basal cell carcinomas (BCCs) [29]. However, little study was performed on the
clinical applications of PDT until 69 years later; Diamond et al. [30] proposed that the
combination of tumor-localizing and phototoxic properties of porphyrins might be ex-
ploited for the treatment of cancer. Later in 1975, Dougherty and coworkers [3] reported
the first case of successful treatment of experimental animal tumors by PDT. In the same
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year, Kelly showed that PDT treatment could destroy human bladder tumor cells trans-
planted into mice [31]. Three year later, Dougherty reported the first successful treatment
of a large series of patients with PDT [32]. Since then, a large number of studies have
been published in support of the clinical effectiveness of PDT for the treatment of various
cancers.
1.2.1 Conventional Mechanism of PDT
Figure 1.1 illustrates some of the processes that can occur after a molecule absorbs a
photon with appropriate energy. The first step is the promotion of the molecule from its
ground electronic state (S0) to an excited singlet state, usually S1. According to Frank-
Condon principle, the time of an electronic transition (on the order of 10−15 s) is much
shorter than that of neclear rearrangement (on the order of 10−13 to 10−14 s) [33]. As a
result, this electronic transition occurs without causing any significant displacement of
the nuclei. If the molecule is promoted to a higher excited singlet state (e.g. S2), it will
undergo a fast internal conversion (IC) to a vibrationally-excited state of S1 (Sv1). This
process is followed by a rapid vibrational relaxation (VR), in which Sv1 loses its excess
energy through collision with solvent molecules. From the lowest, zero-point vibration
level of S1 state (S01), the molecule can go back to its ground state via either radiation
emission (fluorescence) or internal conversion. A crossing from S01 to the excited triplet
state (Tv1) can also take place through another radiationless process, called intersystem
crossing (ISC). A radiative transition known as phosphorescence can bring the molecule
from T01 back to the ground state.
The lifetime of the excited triplet state is typically tens of microseconds due to the
spin-forbidden nature of the T1-S0 transition [34]. In PDT, it is generally believed that
the long lifetime of the excited triplet state allows sufficient time for the photosensi-
tizer to interact with surrounding molecules to produce cytotoxic species. Therefore, the
quenching of the excited triplet state of the photosensitizer (3P∗) is considered to be the
major process to induce photodynamic damages. There are two proposed mechanisms
for the reaction of the 3P∗ with bio-molecules, known as the type I and type II reactions
(Figure 1.2) [11, 34–36].
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Figure 1.1: Jablonski diagram showing the possible fates of a PDT drug molecule fol-
lowing photo-excitation. S0 is the ground electronic state of the molecule. S1 and S2 are
the excited singlet states. T1 is the lowest excited triplet state. (IC: internal conversion;
VR: vibrational relaxation; ISC: intersystem crossing.)
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by electron/hydrogen transfer to produce highly reactive free radicals. Figure 1.2 shows
the reaction with water to generate the hydroxyl radical (.OH) and hydrogen peroxide
(H2O2). A type II reaction, however, produces an electronically excited state of oxygen
known as the singlet oxygen (1O2) through energy transfer.
Figure 1.2: Mechanism of photodynamic photooxidation, adopted from Ref. [11].
At the cellular and tissue levels, the reactive oxygen species (ROS) such as .OH,
H2O2, and
1O2 generated in PDT can cause tumor destruction by direct killing of tumor
cells, damaging the tumor vasculature, or activating an immune response against tumor
growth [37]. Both type I and II processes contribute to the production of ROS and their
contribution depends on the photosensitizing drug used, drug concentration and oxygen
tension [38]. However, it is generally believed that the 1O2 is the most important ROS
generated in PDT [39, 40] and the type II process is the main pathway.
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1.2.2 Singlet Oxygen
Molecular oxygen is one of the most important substances on the earth; it is involved
in all living processes. To a great extent, the special nature of oxygen comes from the
existence of two low lying excited singlet states, namely 1∆g and 1Σ+g . Figure 1.3 shows
the electron occupancy of these two states. In condensed media, the higher energy state
1Σ+g is rapidly converted to
1∆g (i.e. the singlet oxygen).




















Figure 1.3: Electron occupation of molecular orbitals in oxygen.
Since 1O2 has a long lifetime and a low energy level (1∆g→3 Σ−g ,τ = 45 min,v00 =
7882.39 cm−1 [41]), it is the active species in many important photoprocesses [42]. It
can react directly with various types of organic compounds with double bonds. Most of





Biological membranes are the key targets for photomodification in tumor cells fol-
lowing PDT treatment [43–46]. Virtually all components of cell membranes including
phospholipids, proteins and cholesterol are readily oxidized by 1O2. Unsaturated lipids
can be oxidized. The products can then break down to free radicals and initiate chain
oxidation of other unsaturated lipids. In membrane proteins, tyrosine, tryptophan, his-
tidine, methionine, and cysteine are vulnerable [47] and the protein peroxides can also
decompose to generate free radicals. Oxidation of cholesterol by 1O2 produces choles-
terol 5α-hydroperoxide [48].
A key property of a photosensitizer is the quantum yield of singlet oxygen (Φ∆) which
is defined as:
Φ∆ =
The number of 1O2 generated
The number of photons absorbed
(1.1)
In practice, measurements of Φ∆ are usually scaled to standard references such as
rose bengal, which has a Φ∆ of 0.76 in aqueous media [49].
There are three techniques frequently used for the detection and measurement of
singlet oxygen.
Singlet oxygen phosphorescence at 1270 nm: This is a gold standard for 1O2 iden-
tification. In the flash photolysis technique, the sample is irradiated with a strong light
flash. The height of the luminescence pulse is proportional to the yield of 1O2 and the
decay corresponds to the lifetime. The lifetime is highly dependent on the medium. An-
other test for 1O2 is based on the fact that solvent deuteration gives rise to an increase in
the lifetime of more than an order of magnitude [50].
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Protective effects of additives: Indirect methods for 1O2 identification are based on
the inhibiting effects of an additive on the rate of a photochemical reaction. Azide ion
(NG3 ) is a useful water-soluble agent. The protective effect of azide is attributed to physi-
cal quenching. Other frequently used water-soluble quenchers include 1,4-diazabicyclo-
[2.2.2]octane (DABCO), ascorbic acid, and tryptophan. Some 1O2 quenchers used in
organic solvents and phospholipid membranes include cholesterol, -tocopherol and -
carotene.
Electron paramagnetic resonance or electron spin resonance: Singlet oxygen is a
non-magnetic molecule and cannot be detected directly by EPR. However, the reaction of
1O2 with a stable molecule such as 2,2,6,6-tetramethyl-4-piperidone (TEMP) can gener-
ate a moderately long-lived free radical whose structure as determined by EPR provides
an unambiguous identification.
1.2.3 Photosensitizers
The photosensitizer is a critical element in PDT. For the treatment of cancer, an ideal
photosensitizer should meet the following requirements:
• Have the ability to selectively accumulate in the cancerous tissues.
• Have minimum dark toxicity and be cytotoxic in the presence of light.
• Absorb significantly in the tissue optical window [12].
• Have a high quantum yield and long lifetime of triplet state.
• Be rapidly excreted from the body.
More than a century ago, eosin was first used as a photosensitizer to treat epilepsy
[51] and skin tumors [29]. However, the lack of suitable sensitizers and light sources
made it impossible to use PDT clinically at that time. The situation changed in the 1970s
when the ferric ion-free derivative of haem (haematoporphyrin derivative, HpD) and its
purified form porfimer sodium (Photofrinr) became available. The first large series of
successful HpD-mediated PDT treatment in humans were reported by Dougherty et al.
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in 1978. All tumors treated were found to be responsive [32]. Photofrinr was approved
by the U.S. Food and Drug Administration (FDA) in 1995 and has been approved in
several other counties including Canada, Netherlands, Japan, France, and Italy or the
treatment of specific tumors [52]. However, the use of the “first-generation photosensi-
tizers”, including HpD and its commercial variants Photofrinr, Photosanr, Photogemr,
and Photocarcinorinr, is limited to selected tumors due to two important disadvantages.
Firstly, they have the potential of developing severe, prolonged and generalized photo-
toxic reactions in the skin following PDT. Secondly, they are in complex and variable
mixtures forms and have not proved possible to isolate a single active component.
Table 1.1: Photosensitizers that have been approved for clinical uses
Photosensitizer Type of disease Country
Photofrinr Barrett’s HGD Canada, EU, UK, USA
Cervical dysplasia Japan
Cervical cancer Japan
Endobronchial cancer Canada, Denmark, Finland,
France, Germany, Ireland,
Japan, The Netherlands, UK,
USA
Esophageal cancer Canada, Denmark, Finland,
France, Ireland, Japan,
The Netherlands, UK, USA
Gastric cancer Japan
Papillary bladder cancer Canada
ALA (Levalanr, Metvixr) Actinic keratosis EU, USA
ALA (Metvixr) Basal cell carcinoma EU
Foscanr Head and neck cancer EU, Norway, Iceland
ALA: 5-aminolevulinic acid; EU: European Union; HGD: high-grade dysplasia; UK:
United Kingdom; USA: The United States.
Many new compounds have been synthesized in an attempt to create PDT agents
better than Photofrinr. In 1990s, several “second-generation photosensitizers”, includ-
ing 5-aminolaevulinic acid (ALA) and its methyl ester (methyl aminolaevulinate, MAL),
benzoporphyrin derivatives, phthalocyanines, chlorins and porphycenes were developed.
These synthetic dyes are chemically pure, highly efficient, selective and safe. In ad-
dition, the skin photosensitivity of these compounds lasts for only a short time. ALA
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(Levulanr) was approved in 1999 for the treatment of cancerous lesions. The methyl
ester of ALA (Metivxr) was approved in 2001 for the treatmend of BCC and actinic
keratosis. In the same year, mTHPC (temoporfin, Foscanr) was approved for the treat-
ment of head and neck cancer. Table 1.1 is a list of the photosensitizers that have been
approved for clinical uses [38, 53].
1.2.4 Indocyanine Green as a Potential Near Infrared Photosensi-
tizer
The clinic effectiveness of PDT also depends on the wavelength of the light source used.
Light penetration into tissue is limited by light scattering and absorption. The penetration
depth of light in tissue as a function of wavelength has been measured by Eichler et al.
[12]. According to this report, the light penetration depth in tissue between 630 and 690
nm, where most of the currently used photosensitizers are activated, is on the order of 1-2
mm [12]. However, the attenuation of light by tissue is much weaker in the wavelength
range from ∼700 nm to ∼930 nm (the tissue optical window, as shown in Figure 1.4)
[54]. Therefore, one of the approaches to improve PDT efficiency is to develop new
photosensitizers that are sensitive to near infrared (NIR) light.
The dye indocyanine green (ICG, Figure 1.5(a)) was approved by the U.S. FDA in
1956. Since then, it has been widely used in medical diagnosis for blood volume deter-
mination [55], choroidal angiography [56, 57], cardiac output measurement [58], fluo-
rescence probing of proteins [59], and pharmacokinetic analysis [60]. It has also been
considered to be a potential NIR PDT sensitizer. The static absorption spectrum of ICG
(Figure 1.5(b)) shows that it has an absorption maximum of 778 nm in pure water. When
ICG is dissolved in plasma, the absorption peak is shifted to 805 nm [61], falling into the
wavelength range of the human tissue optical window [12].
Potential applications of ICG in PDT have been reported by several groups [62–
65]. Indocyanine green-induced photo-oxidative killing of human cancer cells has been
reported and the involvement of singlet oxygen has been suggested on the basis of the
inhibition effect of the singlet oxygen quencher sodium azide on cell killing [63, 65].
However, direct detection of singlet oxygen luminescence at 1270 nm was unsuccessful
13
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Figure 1.4: Light absorption by four main tissue components: deoxyhaemoglobin (Hb),
oxy-haemoglobin (HbO2), water, and lipids, in the spectral range of 600-1000 nm. The
wavelength range of ∼700 to ∼930 nm is known as the tissue optical window, where the
attenuation of light by tissue is much weaker than that in the other wavelength ranges.
This figure is adapted from [54].
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[66]. Moreover, the triplet quantum yield of ICG was found to be extremely low [67,
68]. Therefore, it is still an open question wether the ROS would be generated via the
conventional mechanism of PDT which involves the long-lived excited triplet state of
the sensitizer. The exact mechanism of drug action, especially the initial photochemical
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Figure 1.5: (a) Structural formula of indocyanine green. (b) Static absorption spectrum
of 10 µM ICG dissolved in water. It has an absorption maximum at 778 nm.
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1.3 Scope of the Thesis
The major objective of this work is to study the very initial reactions that lead to the
generation of reactive oxygen species by ICG, using femtosecond time-resolved laser
spectroscopy. The real-time observations of the reactions have the potential of providing
new insights into the mechanism for the formation of ROS in PDT. This mechanistic
understanding can improve the efficiency of currently used PDT drugs as well as develop
more effective new drugs.
Following this introduction, the principle of femtosecond time-resolved laser spec-
troscopy is briefly described in Chapter 2.
In Chapter 3, the experimental results from the fluorescence up-conversion and pump-
probe transient absorption measurements are presented and discussed. The fluorescence
decay profiles of ICG was obtained from fluorescence up-conversion measurements in
order to determine the lifetime of ICG excited singlet state. The transient kinetic pro-
files of ICG ground state recovery was measured to determine the excited triplet state
quantum yield. Studies on the reaction between ICG and oxgyen was performed by us-
ing pump-probe transient absorption spectroscopy and a new reaction pathway for the
generation of ROS by ICG was proposed.




The major technique that has been applied in this project is the femtosecond time-
resolved laser spectroscopy, which was introduced by the California Institute of Tech-
nology group of Ahmed H. Zewail into the studies of chemical reaction dynamics [69].
2.1 Pump-Probe Transient Absorption Spectroscopy
Figure 2.1: Schematic diagram of the pump-probe transient absorption spectroscopy.
(OPA: optical parametric amplifier)
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Figure 2.1 shows the basic setup for the pump-probe laser spectroscopy. Two laser
pulses with femtosecond duration are used. The “pump” pulse is used to initiate the
reaction, for example, to excite the sample molecules. The “probe” pulse at a chosen
wavelength and delay time is applied to monitor the action of a specific reaction inter-
mediate. Since each species has its own characteristic absorption peak, the behavior
of different reaction intermediates can be observed by changing the probe wavelength.
Different time delays between the pump pulse and the probe pulse can be achieved by
varying the optical path difference (OPD) between these two pulses using a microstep-








an OPD of 1 µm corresponds to a time difference of about 3.3 fs. Therefore, fs time
resolution can be achieved.
2.2 Fluorescence Up-Conversion Technique
Time-resolved fluorescence can be obtained by using the sum-frequency generation (SFG)
technique (i.e., fluorescence up-conversion) [70]. The setup is shown schematically in
Figure 2.2.
In order to achieve fs-resolution, the pump-probe technique is applied. The pump
pulse is used to generate fluorescence emission. The emission from the sample is then
collected by two parabolic mirrors and focused onto a BBO crystal to mix with the probe
pulse which is focused at the same point on the crystal. The SFG at the crystal obeys the
energy and momentum conservation laws as shown by the following equations:
Energy conservation: hν1 +hν2 = hν3; (2.1)
Momentum conservation: h̄
−→
k 1 + h̄
−→
k 2 = h̄
−→
k 3. (2.2)
According to equation (2.1), the energy of the up-converted photon is the sum of
energy of the two incident photons. Thus, the fluorescence signal if in the infrared range
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Figure 2.2: Schematic diagram of the femtosecond-resolved fluorescence up-conversion
technique. (OPA: optical parametric amplifier)
can be converted to visible light and detected by photomultiplier tube (PMT) that is
sensitive to visible light. Equation (2.2) is the phase matching condition which requires
the BBO crystal to be set at specific orientation and angle. Therefore, the amplitude of the
up-converted signal can be optimized by rotating the crystal. Finally, the up-converted
signal is focused at the entrance of a monochromator and the fluorescence decay at a
specific wavelength is then detected by a PMT controlled by a computer program.
2.3 Laboratory at the University of Waterloo
All the experiments of this thesis work were performed in my supervisor Dr. Qing-
Bin Lu’s laboratory in the Department of Physics and Astronomy, at the University of
Waterloo.
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In our laboratory, the standard methodology for pump-probe measurements has been
applied. We used a Ti:sapphire laser system producing 100-120 fs, 1 mJ laser pulses cen-
tered at 800 nm with a repetition rate of 1 kHz. Two optical parametric amplifiers (OPA)
capable of generating pulses with wavelengths from ultra violet (UV, λ ≥ 266 nm) to
near infrared (NIR, several micrometers) were used to produce the pump and probe pulse
respectively. The polarization of the pump and probe pulses was set at the magic angle
54.7◦ in order to avoid contribution from polarization anisotropy due to rotational diffu-
sion of the molecules [71]. Pump energies ≤ 200 nJ were used. The pump and probe
wavelengths of specific measurements are given together with the results. The electronic
devices detecting the signals and the motion controller are integrated into Labview pro-
grams that can directly give the time-resolved absorption or fluorescence kinetic traces.
All decay kinetic traces were fitted to a number of exponential functions by us-
ing a least-squares fitting program. These exponential terms were convoluted with the
instrument-response function represented by a Gaussian function.
All transient absorption and fluorescence measurements were performed at room
temperature in a 5 mm quartz cell with a magnetic stirring bar. All samples were stirred
during measurements to avoid product accumulation.
Ultrapure water with a resistivity of >18 MΩ/cm obtained directly from a Barnstead
Nanopure water system was used.
All static absorption spectra were measured with a UV/Visible/NIR spectrophotome-
ter (Beckman, life sciences).
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Chapter 3
Molecular Reaction Pathway for the
Generation of ROS in PDT with
Indocyanine Green
3.1 Introduction
Photodynamic therapy (PDT) is a potential clinical approach for the treatment of numer-
ous cancers such as the cancers of the bladder [31], prostate [32], and lung [4], as well
as some other nonmalignant conditions such as psoriasis [72] and age-related macular
degeneration (ARMD) [73, 74]. The requirement of the coexistence of both the pho-
tosensitizer and light to cause tissue damage enables precise control of PDT treatment
[75]. The therapeutic effect of PDT is believed to be mainly from the reactive oxygen
species (ROS) generated by the reaction of the excited photosensitizing drug molecule
with oxygen [11]. Although a few PDT sensitizers have been approved for clinical uses,
the molecular mechanisms for drug action, especially the generation of ROS, are poorly
understood. Moreover, currently used photosensitizers are activated within the wave-
length range of 630 to 690 nm. In this wavelength range, the PDT efficiency of these
drugs is limited by the tissue penetration depth of light [11]. One of the approaches to
improve the therapeutic effectiveness of PDT is to develop new drugs that are sensitive
to near infrared (NIR) light.
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Indocyanine green (ICG), which has a strong absorption band between 700 nm and
800 nm coincident with the human tissue optical window [12], is a potential NIR PDT
sensitizer. Indocyanine green-induced photo-oxidative killing of human cancer cells has
been reported [63–65]. The conventional mechanism of PDT gives that the ROS are gen-
erated from the excited triplet state of the photosensitizer through photodynamic reaction
of either type I or type II [11], as described in Chapter 1. According to this mechanism,
the photosensitizing drug should have a high quantum yield and long lifetime of the
triplet state in order to induce significant cancer cell damages. Thus, for PDT studies,
there is a strong need for knowing the triplet state yield of ICG. However, not much in-
formation can be found in the literature, perhaps because of the well known property of
cyanine dyes to have low singlet-triplet intersystem crossing yields [76]. For example,
the maximum ΦT in methanol for carbocyanines was found to be about 3% [77]. In
1997, Reindl et al. determined the triplet state yield of ICG-NaI in various media includ-
ing DMSO (0.17), methanol (0.16), water (0.14) and aqueous albumin solution (0.11)
using a picosecond laser double-pulse fluorescence excitation technique [78]. Later in
1999, the same group obtained a yield of ΦT = 1.7×10−6 in nitrogen-bubbled water by
theoretical fitting to the experimental transmission of the sample [67]. They also came to
the conclusion that indocyanine green solutions were inefficient for triplet-state induced
cell damage in PDT applications. However, the approaches they have applied in these
two studies for the determination of excited triplet-state yield relies on several assump-
tions and, therefore, are indirect. No direct determination of ΦT of ICG was reported
until 2007; the quantum yield of the excited triplet state of ICG in methanol was found to
be extremely low by Sudeep et al., in their study of the photo-induced electron ejection
from the excited state of ICG into TiO2 and Ag@TiO2 core shell nanoparticles [68].
Although Sudeep et al. have obtained direct evidence for the absence of long-lived
species, their measurements were performed in methanol instead of in aqueous solution
which is closer to a biological environment. More importantly, they did not discuss the
generation of ROS by ICG. Therefore, we feel it is still of great importance to study the
behaviors of ICG in water solutions. Moreover, with our femtosecond time-resolved laser
spectroscopy, we are capable of studying the very initial reactions that may lead to the
generation of ROS in PDT, since ICG was found to have a fluorescence lifetime shorter
than 160 ps in water [79]. In this work, we performed a series of experiments on ICG
in aqueous solutions, including fluorescence up-conversion measurements and studies of
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the ground state bleaching, the reaction with oxygen, as well as the concentration effects.
This study should be able to improve our understanding of the molecular mechanism of
PDT.
3.2 Determination of Molar Extinction Coefficient of ICG
The dye indocyanine green (ICG) is a water-soluble tricarbocyanine dye developed in the
Kodak Research Laboratories in 1955. Since its approval by the United States Food and
Drug Administration (FDA) in 1956, ICG has been widely used in medical diagnosis
[55–60, 80, 81]. Despite it’s popularity, the application of ICG is limited due to the
tendency to aggregate, which is the most notable property of the cyanine dyes. Stability
of ICG in aqueous solution has been studied a lot [61, 82–87]. The concentrated solutions
were found to be stable for only 2 days after preparation. A new absorption maximum at
900 nm, which is caused by the formation of J-aggregation, can be formed in about 7 days
after sample preparation [61]. Thus, it is necessary to prepare fresh ICG samples daily
in order to avoid any possible contribution from the aggregation state in the samples.
The Beer-Lambert’s law states that the absorption of light at a certain wavelength (λ )
is directly proportional to the solute concentration (c in M) and the length of the light
path (b in cm), i.e.
A = ε×b× c, (3.1)
where ε in cm−1M−1 is the molar extinction coefficient. According to equation (3.1),
the absorbance of a solute at a fixed wavelength is proportional to its concentration. In
other words, the absorbance and the concentration have a linear relation. Therefore the
concentration of a solution with known ε values can be determined by measuring it’s
absorbance using a spectrophotometer.
It will be more precise to determine the concentration of the stock solution by using
the molar extinction coefficient than from the weight of the solute since only a small
amount of sample (less than 1 mg) is needed for one day’s use. Thus for the purpose of




ICG (molecular weight 774.98) was purchased from Sigma-Aldrich and used as supplied.
A stock solution of 1 mM was prepared by dissolving 1.1 mg ICG powder in 1.419 ml
ultrapure water. Static absorption spectra of diluted samples with concentrations of 1,
2, 3, 4, 5, 10, and 20 µM, respectively, were then measured by using a UV/Visible/NIR
spectrophotometer (Beckman, life sciences).
3.2.2 Results and discussion
The Beer-Lambert’s law is obeyed in a certain range of concentration. In the case of
ICG, the departure from the Beer-Lambert’s law becomes significant when the sample
concentration is higher than 10 µM (in water) due to the formation of H-aggregation
[83, 88]. Therefore, only the results of samples with concentrations of 1, 2, 3, 4, and 5
µM were used to determine the ε value.
Figure 3.1(a) shows the static absorption spectra of these ICG samples. Figure 3.1(b)
is the plot of the absorbance value at 778 nm against the sample concentration. Ac-
cording to equation (3.1), a linear relation between the absorbance value and the sample
concentration should be obtained. A linear fit to the experimental data gave a slope of
k = 0.224 with an R2 of 0.9997. So the molar extinction coefficient of ICG dissolved in











This value agrees well with the reported value of ε = 2.05× cm−1M−1 in water [89]
and, therefore, was used to control the concentration of the samples in later experiments.
3.3 Fluorescence Up-Conversion Measurements
Fluorescence measurements are the most direct way for the determination of the S1 state
lifetime, without contribution from vibrational relaxation and solvation effects. With
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Figure 3.1: (a) Static absorption spectra of various concentrations of ICG (1, 2, 3, 4, and
5 µM) in water measured in 1 cm polystyrene cuvettes. (b) Plotting of the absorbance
value at 778 nm as a function of the sample concentration. A linear fitting to the experi-
mental data gives a slope of 0.224 with an R2 of 0.9997.
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our fs laser spectroscopy, we have performed femtosecond time-resolved fluorescence
studies on ICG using fluorescence up-conversion technique which is extremely attractive
for time-resolved fluorescence studies due to the availability of excellent photomultiplier
tubes (PMTs) in the UV and blue regions.
3.3.1 Experimental details
ICG samples with a concentration of 25 µM were diluted from a stock solution of 1.13
mM. The excitation wavelength was set at 800 nm and the pump pulse energy was 200
nJ. The collected fluorescence emission was mixed with the probe pulse set at 800 nm
to generate the up-converted signal. A blue bandpass filter (BG40, Newport Corpora-
tion) was place in front of the monochromator to allow the up-converted light to pass
through and block the fluorescence light as well as the 800 nm light. The fluorescence
decay kinetics at three different wavelengths, i.e. 870 nm, 900 nm, and 930 nm were
recorded by setting the monochromator at 417 nm, 424 nm, and 430 nm respectively.
Fluorescence of shorter wavelengths were not measured since there was more contribu-
tion from the 400 nm light generated by the crystal from the probe pulse than that from
the up-converted fluorescence signal at these wavelengths. For wavelengths longer than
930 nm, fluorescence profiles were not measured since the signal became too weak to
get a high signal-to-noise ratio.
3.3.2 Results and discussion
Fluorescence decay kinetic traces of ICG at three different wavelengths are presented in
Figure 3.2. All decays were adequately fitted by a single-exponential function and the
decay lifetime was determined to be 155 ps, 147 ps, and 145 ps, respectively. Attempts
to fit the data to a double-exponential function did not give better results. This lifetime
of around 150 ps was attributed to be the lifetime of the excited singlet state of ICG. No
long-lived species were observed in this experiment.
Studies on the fluorescence properties of ICG in various media can be found in the
literature [79, 88]. Soper et al. determined the fluorescence lifetime of ICG in methanol,
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Figure 3.2: Femtosecond time-resolved fluorescence decay kinetic traces of 25 µM ICG
in water at three different wavelength. The excitation wavelength was 800 nm with an
energy of 200 nJ. The solid lines are the best fits to the experimental data.
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water, methanol/water binary mixture, D2O, SDS and Triton X-100 directly from the flu-
orescence decay profiles [79]. They reported a τF value of 470 ps in 100% of methanol
and τF = 160 ps in a binary mixture consisting of 75% of H2O and 25% of methanol.
Unfortunately, the lifetime of ICG in 100% water could not be determined with the res-
olution of their NIR time-correlated single photon counting (TCSPC) device. In 1996,
Philip et al. calculated a fluorescence lifetime of 20 ps in water [88]. However, in this
report, the τF value in methanol was determined to be 190 ps which was much shorter
than 470 ps reported in Ref .[79]. Moreover, Sudeep et al. have obtained a τF = 410±10
ps (in methanol) [68] consistent with the value of 470 ps in Ref .[79] rather than 190 ps in
Ref .[88]. This difference is probably due to the different approaches used. Philip et al.
obtained their values through complicated calculations using their fluorescence quantum
distributions data while Soper et al. and Sudeep et al. determined the lifetime directly
from the decay profiles.
We are the first to obtain fluorescence decay profiles of ICG in water by using our
femtosecond time-resolved fluorescence up-conversion spectroscopy. The lifetime of
1ICG∗ have been determined to be around 150 ps.
3.4 Ground State Recovery of ICG
The determination of the excited triplet state quantum yield of the photosensitizer is es-
pecially important for PDT applications. Numerous procedures have been developed
including fluorescence quenching [90], triplet-sensitized isomerization [91], delayed flu-
orescence measurements [92], electron spin resonance [93], laser flash absorption and
relative actinometry [94], and time-resolved photothermal techniques [95]. However,
these methods have their disadvantages since they often rely on very careful calibration,
an external standard, or measurements performed in ratio mode such as comparison of
fluorescence intensities. Lament et al. have developed a simple procedure for the de-
termination of ΦT which uses transient kinetic profiles of ground state recovery of the
compound under investigation and thus avoids the need for a relative measurement [96].
Figure 3.3 shows the principle of ground state bleaching measurements. Without
excitation, all molecules are in the ground state (as shown in Figure 3.3(a)). When the
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pump pulse comes, some of the molecules get excited and go to the excited singlet state
resulting in a decrease of the number of molecules in the ground state (Figure 3.3(b)).
( d )( c )
( b )S 1 T 1
S 0
S 1 T 1
S 0
S 1 T 1
S 0
S 1 T 1
S 0
( a )
Figure 3.3: Schematic diagram showing the principle of ground-state bleaching mea-
surements.
This will give rise to a decrease in the absorbance at specific wavelengths where
the molar extinction coefficient of the ground state is much higher than that of the ex-
cited state. Thus a negative signal is generated. The recovery of this negative signal
corresponds to the relaxation of the excited molecules back to the ground state (Figure
3.3(d)). A 100% recovery will be observed if all the molecules go back to S0 within
the time of the measurement. However, a 100% recovery can not always be achieved
if a large number of molecules go to the long-lived T1 state through a process called
inter-system crossing (ISC) (Figure 3.3(c)).
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3.4.1 Experimental details
ICG sample with a concentration of 10 µM was diluted from a stock solution of 256
µM. In this experiment, the probe wavelength was set at 800 nm, where the absorption
of the ground state of ICG is dominating, and the pump wavelength was 400 nm, with an
energy of 40 nJ.
3.4.2 Results and discussion
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Figure 3.4: The ground-state bleaching recovery trace of 10 µM ICG in water. The
pump wavelength was 400 nm with an energy of 40 nJ and the probe wavelength was
800 nm. The solid line is the best fit to the experimental data, giving a decay time of
τ=155 ps. The recovery of ICG ground-state at the time delay of 800 ps was calculated
to be 99.4%.
The result is shown in Figure 3.4. The best fit to the experimental data gives a single
recovery lifetime of 155 ps, which is consistent with the lifetime of ICG excited singlet
state obtained from fluorescence measurement. In addition, a recovery of about 99.4%
was achieved at the time delay of 800 ps. These results indicate that ICG has an extremely
low quantum yield of excited triplet state (Φ3ICG∗ < 0.6%) in water.
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The result of this experiment confirms that the lifetime of 1ICG∗ in water is about
150 ps rather than the reported value of 20 ps [88].
A low quantum yield of the excited triplet state of ICG is expected [67, 76]. Values
of ΦT have been reported previously [67, 68, 78]. By using a picosecond laser double-
pulse fluorescence excitation technique [97], Reindl et al. were the first to measure the
quantum yields of ICG in various media including DMSO, methanol, water, and aqueous
albumin solution. The reported ΦT values of ICG in water and methanol were 0.14 and
0.16 respectively [78]. However, later in 1999, the same group reported different values
of ΦT = 1.7× 10−6 (in water) and ΦT = 2.3× 10−5 (in methanol), and concluded that
ICG was inefficient for PDT applications [67]. No explanation was given about the
inconsistence of the values. More recently, Sudeep et al. obtained the bleaching trace of
ICG in methanol at 750 nm which suggested the absence of long-lived species [68]. Our
studies on the ground-state recovery of ICG shows that ΦT in water is also extremely
low.
Considering it’s low yield of excited triplet state, we can rule out the following two
possible reaction pathways that may contribute to the generation of ROS by ICG.
3ICG∗+3 O2→ ICG+1 O2; (3.2)
1ICG∗+3 O2→3 ICG∗+1 O2. (3.3)
Both reactions involve the 3ICG∗. Reaction (3.2) involves energy transfer from 3ICG∗
to ground state oxygen to produce 1O2. Since the quantum yield of 3ICG∗ has been found
to be extremely low, it is unlikely that large amount of 1O2 could be generated through
this pathway. Reaction (3.3) is the generation of 1O2 from 1ICG∗. If this reaction did take
place, large amount of 3ICG∗ should have been produced too, which was not observed.
So this reaction can also be ruled out. Then for photosensitizers with low triplet state
quantum yields such as ICG, there might exist a new reaction pathway for the generation
of ROS which does not involve the long-lived excited triplet state of those compounds.
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3.5 Reaction Between ICG and Oxygen in Water
Femtosecond time-resolved transient absorption laser spectroscopy is one of the most
powerful technique for direct examination of the reaction dynamics [69]. In order to
reveal the molecular mechanism for the generation of the ROS in ICG-mediated PDT,
we performed real-time studies on the reaction between ICG and O2 in water.
3.5.1 Experimental details
In this experiment, two 10 µM ICG samples were diluted from a stock solution of 884
µM and bubbled with O2 and N2, respectively. Transient absorption decay kinetic traces
were measured for both samples immediately after bubbling. Static absorption spectra
of both samples were recorded too. In the following day, both transient absorption decay
kinetic traces and static absorption spectra of these two samples were recorded again
after being kept in dark at 4 ◦C for 17 hours. In the transient absorption measurements,
the pump was set at 800 nm with an energy of 48 nJ and the probe wavelength was 615
nm.
3.5.2 Results and discussion
Figure 3.5(a) shows the original data of femtosecond time-resolved transient absorption
decay kinetic traces of all the samples. We noted that the intensity of the initial peaks
of both samples decreased by ∼ 40% after being kept in dark for 17 hours. This was
due to a decrease in the sample concentration [61, 82]. To eliminate this concentration
effect, all curves were normalized to their initial peaks. The normalized traces (Figure
3.5(b)) showed no difference between the O2-bubbled sample and the N2-bubbled one
immediately after the bubbling. However, a dramatic change in the sample with O2 could
be seen after being kept in dark for 17 hours, while there was no significant change in
the sample with N2.
The normalized static absorption spectra of all these samples are shown in Figure
3.6. A broadening of the absorption band and an enhancement of the absorption at ∼710
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Figure 3.5: (a) is the original data of the femtosecond time-resolved transient absorption
decay kinetic traces of 10 µM ICG in water. (b) is the transient absorption decay kinetic
traces normalized at the initial peaks. The pump wavelength was 800 nm with an energy
of 48 nJ and the probe wavelength was 615 nm.
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Figure 3.6: The normalized static absorption spectra of all the samples.
nm were clear for the O2-bubbled sample after being kept in dark for 17 hours. These
results indicated the existence of interactions between ICG and O2 in the ground state.
However, we noted that the enhanced absorption at∼710 nm was similar to the behavior
of ICG H-aggregation, which was characterized by a blue shift in the main absorption
peak [98]. Thus further studies were required in order to determine whether the change
of ICG sample in the presence of O2 was due to the formation of the H-aggregation.
3.6 Concentration Effect of ICG in Water
Indocyanine green easily aggregates in aqueous solutions; the H-aggregate states can
be obtained simply by increasing its concentration [61, 88]. Therefore, we studied the
concentration effect of ICG in water in order to determine whether the change in the
transient absorption signals is related to the formation of H-aggregation.
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3.6.1 Experimental details
In this experiment, three ICG samples with concentrations of 3, 5, and 10 µM were
diluted from a stock solution of 244 µM. Both the transient absorption decay kinetic
traces and the static absorption spectra of all three samples were recorded. In the transient
absorption measurements, the pump pulse was set at 800 nm with an energy of 48 nJ and
the probe wavelength was 615 nm.
3.6.2 Results and discussion
Both the transient and static absorption curves of all three samples (3, 5, and 10 µM) have
been obtained. The normalized static absorption spectrum of the 10 µM sample showed
an enhanced absorption at ∼710 nm (Figure 3.8(b)) indicating the existence of ICG H-
aggregation in this sample. However, no difference among these samples was observed in
the normalized transient absorption signals (Figure 3.7(b)). This result suggested that the
H-aggregate states of ICG had no contribution to the transient absorption measurements
performed earlier. Thus the change in the transient kinetic trace observed in the sample
with O2 did not involve the formation of the H-aggregate states; it implied the interaction
between ICG and O2. This interaction was assigned to be the formation of ICG and O2
complexes in their ground states ([ICG]m:[O2]n) based on the fact that the change was
significant only when the sample had been kept for a long time in the presence of O2.
The formation of the [ICG]m:[O2]n might be able to induce a broadening of the static
absorption band as well.
3.7 Transient Absorption Spectra of ICG
The ICG and oxygen complexes, if formed, should exhibit distinct absorption character-
istics. All the transient absorption kinetic profiles obtained (Figure 3.5 and Figure 3.7)
showed two distinct decay components indicating the existence of two transient species.
Therefore, we also performed transient absorption spectra measurements to obtain the
transient absorption kinetics of ICG at different probe wavelengths.
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Figure 3.7: Femtosecond time-resolved transient absorption decay kinetic traces of three
different concentrations of ICG (3, 5, and 10 µM) in water: (a) shows the original data;
(b) shows the normalized traces. The pump wavelength was 800 nm with an energy of
48 nJ and the probe wavelength was 615 nm.
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Figure 3.8: Static absorption spectra of three different concentrations of ICG (3, 5, and
10 µM) in water: (a) shows the original data; (b) shows the normalized spectra.
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3.7.1 Experimental details
The setup in this experiment was similar to that of the pump-probe absorption spec-
troscopy described earlier in Chapter 2 with the following modifications:
1. A white light continuum (WLC) probe was used instead of the single color pulse.
2. A monochromator was used to select the wavelength.
3. The photodiode detector was replaced by a photomultiplier tube.
In order to obtain the transient absorption spectra at a specific time delay, we moved
the microstepping motor stage to a certain position and then made the monochromator to
do wavelength scanning. When measuring the transient absorption decay traces, we set
the monochromator to a specific wavelength and moved the microstepping motor stage
to get the time-resolved results.
ICG samples with a concentration of 30 µM were diluted from a stock solution of 1
mM which had been kept in dark for 2 days. The pump wavelength was 800 nm with an
energy of 200 nJ. The step of the monochromator was 3 nm for the transient absorption
spectra measurements.
3.7.2 Results and discussion
Femtosecond time-resolved transient absorption spectra of 30 µM ICG in water at differ-
ent five pump-probe time delays following the laser pulse excitation are shown in Figure
3.9. The absorption spectra covers the whole visible range with an absorption maximum
at about 560 nm. The negative absorption starting from ∼620 nm comes from the strong
absorption of the dye molecules in the ground state. The normalized spectra (Figure
3.9 (b)) shows that the absorption intensity does not decrease monotonically at all probe
wavelengths, suggesting the existence of two distinct species in this sample.
In order to determine the lifetimes of this two species, we also measured the fem-
tosecond time-resolved transient absorption decay kinetic traces of ICG samples at four
different wavelengths (i.e. 500 nm, 520 nm, 560 nm, and 600 nm) (Figure 3.10).
38
4 0 0 4 5 0 5 0 0 5 5 0 6 0 0
- 0 . 0 1
0 . 0 0
0 . 0 1
0 . 0 2
0 . 0 3
 
 
 1  p s
 3  p s
 1 1  p s
 3 8  p s
 1 5 8  p s










4 0 0 4 5 0 5 0 0 5 5 0 6 0 0



















e  1  p s
 3  p s
 1 1  p s
 3 8  p s




Figure 3.9: Femtosecond time-resolved transient absorption spectra of 30 µM ICG in
water recorded at the visible region. The pump wavelength was 800 nm with an energy
of 200 nJ and the probe pulse was white light continuum. The spectra were measured
at five different pump-probe time delays following excitation. (a) are the original data
showing that the excited singlet state of ICG has a broad absorption band in the visible
range, with a absorption peak at 560 nm. (b) are the normalized spectra.
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Figure 3.10: Femtosecond time-resolved transient absorption decay kinetic traces of 30
µM ICG in water at four different wavelengths (i.e. 500 nm, 520 nm, 560 nm, and 600
nm). The pump wavelength was 800 nm with an energy of 200 nJ and the probe pulse
was white light continuum. The solid line is the best fit to the experimental data.
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At all wavelengths measured, the traces showed two distinct decay components sug-
gesting the coexistence of two transient species. The best fits to the experimental data
always gave a single rising lifetime of 276±61 fs, and two decay lifetimes of 3.35±0.56
ps and 132± 16 ps, respectively. The results of the fitting were summarized into Table
3.1.
Table 3.1: The results of the best fits to the transient absorption decay kinetic traces
at four different probe wavelengths: τ1 is the rising lifetime; τ2 and τ3 are the decay
lifetimes; A1, A2, and A3 are the pre-exponential factors, respectively.
λprobe (nm) A1 A2 A3 τ1 (fs) τ2 (ps) τ3 (ps) A2/A3
500 -0.012 0.010 0.003 336±61 2.53±0.56 117±16 3.33
520 -0.029 0.016 0.007 309±61 3.66±0.56 120±16 2.29
560 -0.045 0.016 0.011 196±61 3.77±0.56 150±16 1.45
600 -0.026 0.014 0.004 263±61 3.45±0.56 140±16 3.50
Average – – – 276±61 3.35±0.56 132±16 –
The rising lifetime of 276± 61 fs corresponds to the formation time of the excited
states. The long decay lifetime of 132± 16 ps is consistent with the lifetime of 1ICG∗
obtained in the previous experiments. We have attributed the short decay lifetime of
3.35± 0.56 ps to the lifetime of [ICG∗]m:[O2]n. This assignment is also supported by
the similar observation that the ICG/CDDP complexes have a short decay lifetime of ∼5
ps [99]. Moreover, we have found that the two transient species contribute differently to
the absorption spectra by calculating the ratios of the pre-exponential factor A2 to A3 at
different wavelengths. As shown in the last column of Table 3.1, a minimum of the value
at 560 nm indicates a more significant contribution from 1ICG∗ at this wavelength than
the other wavelengths. This is illustrated more clearly in the plot of the pre-exponential
factors against the probe wavelength (Figure 3.11). The absorption of 1ICG∗ shows
a peak at 560 nm, which agrees well with the reported value [68, 100], while that of
[ICG∗]m:[O2]n exhibits a much broader band with a blue-shifted absorption maximum at
around 540 nm.
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Figure 3.11: The plot of the pre-exponential factors, obtained from the multi-exponential
fit of the transient absorption traces, against the probe wavelength.
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3.8 Proposed Reaction Mechanism
Basing on all these observations, we have proposed the following reaction pathway:
ICG+O2→ [ICG]m : [O2]n;
[ICG]m : [O2]n +hν → [ICG]
∗
m : [O2];
[ICG]∗m : [O2]→ ICG
+•+O−•2 .
The first step is the formation of ICG and oxygen complexes in their ground states.
Although this is a rather slow process, once formed, these complexes can dissociate
rapidly upon photo-excitation to generate highly reactive species that can cause severe
damages to the cancerous tissues.
The Rehm-Weller equation [101] is widely used for calculating the free energy changes
associated with photo-induced electron transfer (PET) reactions. It can be written as
∆G(eV) = nF[Eox−Ered]−wp−E00, (3.4)
where n is the number of electrons transferred, F is the Faraday’s constant, Eox is the ox-
idation potential of the donor, Ered is the reduction potential of the accepter, wp describes
the coulombic attraction between ions generated by electron transfer, and E00 is the en-
ergy of the excited sate. For most electron transfer reactions, nF is approximately equal
to one and can be disregarded in the calculations. The work term, wp, is not applicable
to cases where electron transfer occurs between a charged and neutral species, due to the
lack of electrostatic attraction between the species, and can therefore be disregarded.
The oxidation potential of ICG in water is 0.76 eV vs Ag/AgCl [89]. The reduction
potential for O2/O
–
2 in water is −0.53 eV vs Ag/AgCl (−0.33 eV vs NHE [102]). With
an excitation energy of E00 = 1.55 eV, the free energy change of the electron transfer
from ICG∗ to O2 can be estimated by using equation 3.4:
∆G(eV) = [0.76− (−0.53)]−1.55 =−0.26 eV (−6.00 kcal/mol) < 0.
Therefore, the electron transfer reaction between ICG∗ and O2 is energy favorable.
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In principle, the transient species (i.e. ICG+• and O−•2 ) produced by the electron
transfer reaction between ICG and O2 can be detected according to their absorption prop-
erties.
Detection of ICG cation radical: Sudeep et al. have obtained the transient absorp-
tion spectra of ICG cation generated by the radiolysis of O2 saturated solution in methy-
lene chloride [68]. The dye cation exhibits a broadband in the visible region. However,
the absorption band of ICG+• overlaps with that of ICG∗. Thus it is difficult to separate
these two species. Moreover, the electron back transfer reaction might have reduced the
lifetime of ICG+• to be on the scale of the lifetime of ICG∗ [68]. This effect makes the
work of identifying ICG+• even more challenging.
Detection of superoxide anion radical: Superoxide anion has an absorption band
in the UV range with an absorption maximum at around 240 nm [103]. However, ICG
also has strong absorption in this region (Figure 1.5). When using a 266 nm pulse as the
probe, we obtained a transient absorption curve similar to Figure 3.4 showing the strong
absorption from the ground state of ICG. Therefore, for the detection of O−•2 , a proper
probe wavelength has to be chosen in order to minimize the contribution from ICG. This
is extremely difficult since the molar extinction coefficient of ICG is one order of mag-
nitude larger than that of the superoxide anion. Another problem is that the intensity of
our WLC in the UV range is far too weak to be used as the probe for transient absorption




We have performed high-sensitivity time-resolved femtosecond laser spectroscopic ex-
periments on indocyanine green (ICG), which is a potential near infrared (NIR) photo-
sensitizing drug for photodynamic therapy (PDT) applications. For the first time, we
studied the initial photochemical reactions leading to the generation of reactive oxygen
species (ROS) by using our femtosecond time-resolved laser spectroscopy.
We have obtained the femotosecond time-resolved fluorescence decay kinetic traces
of ICG in aqueous solution by applying fluorescence up-conversion technique. The life-
time of the excited singlet state of ICG has been determined to be about 150 ps directly
from the fluorescence decay profiles.
The results of the ground state bleaching recovery experiment indicate that ICG has
an extremely low yield of excited triplet state (Φ3ICG∗ < 0.6%) in water. Thus, it is
unlikely that large amount of ROS could be generated from the excited triplet state of
ICG. This finding is contrary to the conventional understanding that major pathway for
ROS generation is the long-lived excited triplet state of the photosensitizers reacting with
oxygen molecule. Therefore, there may exist a new reaction pathway for the generation
of the ROS, which does not involves the long-lived excited triplet state of drugs.
The results of further studies show that the formation of ICG and oxygen ground-state
complexes ([ICG]m:[O2]n) is a key step in the generation of ROS. Although the formation
of this complex is a slow process, the complex can dissociate rapidly, with a lifetime of
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about 3.35 ps, upon photoexcitation to produce highly reactive species that can cause tis-
sue damages. A possible reaction pathway is the electron transfer from the excited state
of ICG to ground state oxygen, since this reaction has been found to be exothermic from
free energy change calculation. In principle, the products of the electron transfer reaction
can be detected at proper probe wavelengths. However, the strong and broadband absorp-
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